title: Executive summary of the consensus document on metabolic disorders and cardiovascular risk in patients with HIV infection.
abstract: The importance of the metabolic disorders and their impact on patients with HIV infection requires an individualized study and continuous updating. HIV patients have the same cardiovascular risk factors as the general population. The HIV infection per se increases the cardiovascular risk, and metabolic disorders caused by some antiretroviral drugs are added risk factors. For this reason, the choice of drugs with a good metabolic profile is essential. The most common metabolic disorders of HIV infected-patients (insulin resistance, diabetes, hyperlipidemia or osteopenia), as well as other factors of cardiovascular risk, such as hypertension, should also be dealt with according to guidelines similar to the general population, as well as insisting on steps to healthier lifestyles. The aim of this document is to provide a query tool for all professionals who treat HIV-patients and who may present or display any metabolic disorders listed in this document.
authors.forename: Rosa
authors.initials: R
authors.lastname: Polo Rodríguez
authors.forename: María José
authors.initials: MJ
authors.lastname: Galindo Puerto
authors.forename: Carlos
authors.initials: C
authors.lastname: Dueñas
authors.forename: Carmen
authors.initials: C
authors.lastname: Gómez Candela
authors.forename: Vicente
authors.initials: V
authors.lastname: Estrada
authors.forename: Noemí G P
authors.initials: NG
authors.lastname: Villar
authors.forename: Jaime
authors.initials: J
authors.lastname: Locutura
authors.forename: Ana
authors.initials: A
authors.lastname: Mariño
authors.forename: Javier
authors.initials: J
authors.lastname: Pascua
authors.forename: Rosario
authors.initials: R
authors.lastname: Palacios
authors.forename: Miguel Ángel
authors.initials: MÁ
authors.lastname: Von Wichmman
authors.forename: Julia
authors.initials: J
authors.lastname: Álvarez
authors.forename: Victor
authors.initials: V
authors.lastname: Asensi
authors.forename: José
authors.initials: J
authors.lastname: Lopez Aldeguer
authors.forename: Fernando
authors.initials: F
authors.lastname: Lozano
authors.forename: Eugenia
authors.initials: E
authors.lastname: Negredo
authors.forename: Enrique
authors.initials: E
authors.lastname: Ortega
authors.forename: Enric
authors.initials: E
authors.lastname: Pedrol
authors.forename: Félix
authors.initials: F
authors.lastname: Gutiérrez
authors.forename: Jesús
authors.initials: J
authors.lastname: Sanz Sanz
authors.forename: Esteban
authors.initials: E
authors.lastname: Martínez Chamorro
mesh_terms: D019380:Anti-HIV Agents / Q000009:adverse effects; D002318:Cardiovascular Diseases / Q000453:epidemiology* / Q000517:prevention & control; D015897:Comorbidity; D015444:Exercise; D015658:HIV Infections / Q000453:epidemiology*; D006293:Health Promotion; D000070497:Healthy Lifestyle; D006801:Humans; D052439:Lipid Metabolism Disorders / Q000139:chemically induced / Q000453:epidemiology; D008659:Metabolic Diseases / Q000139:chemically induced / Q000453:epidemiology* / Q000628:therapy; D012307:Risk Factors; D012735:Sexual Dysfunction, Physiological / Q000453:epidemiology / Q000209:etiology; D016540:Smoking Cessation
chemical_list: D019380:Anti-HIV Agents
keywords: Alteraciones metabólicas; Cardiovascular risk; HIV infection; Infección por VIH; Metabolic disorders; Riesgo cardiovascular